Towards a Future That Creates Abundance for Humanity
The global Pharma industry is said to be a huge and growing market in the world.
We're a stem cell bio-venture company conducting research and development.
The goal is to illuminate the future of the humanity with the latest medical science that utilizes genetic research and biotechnology, with drugs that are appreciate for individual patients and have fewer side effects.
Our research and development professionals have built a top-level development system, and are working every day to create better medicines and a better world.
As a global company, we'll partner with research institutions and Pharma companies to research cutting-edge medicines as well as to make a better world by developing new therapies.
We, bio-venture companies, support people's healthy and secure lives through prevention and treatment of diseases directly related to health.
We develop and manufacture regenerative medicine products under strict legal regulations including the Pharmaceutical Affairs Law, which is essential to ensure the efficacy and safety of such products.
Cell therapy is a treatment method that uses your own cells or the cells of others to treat diseases. Oligogen is developing a new treatment for neurological diseases for which there has been no treatment using its proprietary neural stem cells, OligoGenie.
Exosomes are very small vesicles secreted by cells and are beginning to be applied in cancer diagnosis and disease treatment. Oligogen is developing an exosome preparation that may be useful in the treatment of neurological diseases and plans to apply it to the treatment of neurological diseases such as Alzheimer's disease and multiple sclerosis.
Drug discovery is the process of finding compounds and chemicals (sometimes called seeds or lead compounds) that will become the source of pharmaceuticals until they are marketed as products. Oligogen is developing a drug screen system to discover compounds and chemicals for the treatment of demyelinating diseases and neurodegenerative diseases using neural stem cell OligoGenie.
On November 7, 2023, our CEO, Mr. Kido, gave a short presentation at the “Kyoto City Growth Industry Creation Center (ACT Kyoto) 10th Anniversary Forum“.
Events（CY2022-）
Our representative participated in the “KLSAP2023 Pitch Event” held at Creative Lab Kobe on July 14, 2023, and spoke at the “Pitch Competition”.
Events（CY2022-）
●Aug. 2017：Raised investment funds (Series A-1) from four venture capital firms ●Jan. 2020：Raised additional investment funds (Series A-2) from two venture capital firms ●Nov. 2021：Raised funds for investment by issuing new share subscription rights at Japan Crowd Capital “FUNDINNO”
Funding
